Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Rilematovir in Healthy Male Subjects
NCT03002779Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilematovir in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Primary endpoints: Mass Balance of JNJ-53718678 at Day 10 and Metabolic profiles of JNJ-53718678 at Day 6. Started Jan 2017; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03002779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002779.